Cerus Corporation
Index- P/E- EPS (ttm)-0.28 Insider Own3.10% Shs Outstand174.48M Perf Week2.87%
Market Cap817.43M Forward P/E- EPS next Y-0.24 Insider Trans-12.81% Shs Float171.39M Perf Month4.81%
Income-49.20M PEG- EPS next Q-0.07 Inst Own80.00% Short Float5.16% Perf Quarter-7.22%
Sales173.00M P/S4.73 EPS this Y13.00% Inst Trans0.37% Short Ratio4.65 Perf Half Y-31.28%
Book/sh0.46 P/B10.89 EPS next Y14.30% ROA-21.80% Target Price9.40 Perf Year-14.51%
Cash/sh0.67 P/C7.53 EPS next 5Y- ROE-59.90% 52W Range4.38 - 8.06 Perf YTD-26.43%
Dividend- P/FCF- EPS past 5Y12.50% ROI-32.00% 52W High-37.80% Beta1.17
Dividend %- Quick Ratio2.20 Sales past 5Y32.40% Gross Margin59.30% 52W Low14.38% ATR0.36
Employees294 Current Ratio2.60 Sales Q/Q45.30% Oper. Margin-24.50% RSI (14)50.58 Volatility6.80% 7.92%
OptionableYes Debt/Eq0.88 EPS Q/Q31.90% Profit Margin-28.40% Rel Volume1.21 Prev Close5.01
ShortableYes LT Debt/Eq0.69 EarningsMay 05 AMC Payout- Avg Volume1.90M Price5.01
Recom1.40 SMA202.94% SMA50-1.87% SMA200-15.96% Volume0 Change0.00%
Oct-08-20Resumed BTIG Research Buy $9
Jun-16-20Resumed Cantor Fitzgerald Overweight $9
Feb-26-20Initiated BTIG Research Buy $7
Nov-13-19Upgrade BTIG Research Neutral → Buy $7
Aug-28-19Initiated Stifel Buy
Aug-23-19Resumed Stephens Overweight
Jan-05-18Resumed Cantor Fitzgerald Overweight
Dec-08-17Resumed BTIG Research Neutral
Jul-07-16Resumed Cantor Fitzgerald Buy $9
Dec-17-15Downgrade Wedbush Outperform → Neutral
May-02-14Reiterated MLV & Co Buy $8.50 → $6
Apr-24-13Reiterated Cantor Fitzgerald Buy $5.50 → $6
Mar-15-13Reiterated MLV & Co Buy $7.50 → $8.50
Apr-17-12Initiated Cantor Fitzgerald Buy $5.50
Feb-29-12Upgrade Robert W. Baird Neutral → Outperform $3 → $6
Nov-10-11Reiterated MLV & Co Buy $4 → $5
Jun-03-11Initiated Wedbush Outperform $4
Mar-04-11Downgrade Robert W. Baird Outperform → Neutral $4 → $3
Mar-09-10Upgrade Robert W. Baird Neutral → Outperform $3 → $5
Aug-26-09Upgrade Avondale Mkt Perform → Mkt Outperform $2 → $5
May-17-22 05:00AM  
May-16-22 09:55AM  
May-15-22 08:42AM  
May-06-22 02:30AM  
May-05-22 05:15PM  
May-03-22 08:00AM  
Apr-28-22 08:35AM  
Apr-25-22 08:00AM  
Apr-21-22 08:00AM  
Apr-07-22 11:39AM  
Feb-25-22 08:00AM  
Feb-23-22 10:00AM  
Feb-22-22 10:00PM  
Feb-08-22 08:00AM  
Feb-07-22 04:05PM  
Feb-04-22 05:36AM  
Jan-28-22 01:38PM  
Jan-10-22 08:00AM  
Dec-28-21 10:00AM  
Dec-06-21 04:43AM  
Nov-24-21 10:00AM  
Nov-19-21 08:00AM  
Nov-10-21 11:43AM  
Nov-08-21 10:06AM  
Nov-03-21 12:03PM  
Nov-02-21 05:25PM  
Oct-29-21 08:47AM  
Oct-26-21 03:02PM  
Oct-19-21 08:00AM  
Oct-18-21 12:26PM  
Oct-07-21 06:49AM  
Oct-01-21 08:00AM  
Sep-20-21 08:00AM  
Sep-15-21 08:00AM  
Aug-15-21 01:26PM  
Aug-10-21 08:30AM  
Aug-04-21 08:30AM  
Aug-03-21 05:15PM  
Jul-27-21 03:02PM  
Jul-20-21 08:30AM  
Jul-14-21 08:30AM  
Jun-30-21 08:30AM  
Jun-14-21 08:30AM  
Jun-05-21 04:16AM  
May-17-21 09:00AM  
May-05-21 09:30AM  
May-04-21 05:35PM  
Apr-20-21 08:30AM  
Apr-06-21 02:46AM  
Mar-03-21 08:30AM  
Feb-26-21 10:01AM  
Feb-25-21 04:01PM  
Feb-24-21 05:00PM  
Feb-11-21 08:30AM  
Feb-05-21 01:39AM  
Feb-04-21 08:30AM  
Jan-23-21 11:30PM  
Jan-11-21 08:30AM  
Dec-15-20 08:30AM  
Dec-11-20 10:55PM  
Dec-07-20 12:11AM  
Dec-04-20 07:00PM  
Nov-30-20 12:00PM  
Nov-20-20 12:00PM  
Nov-12-20 08:30AM  
Nov-01-20 07:59AM  
Oct-30-20 03:30PM  
Oct-29-20 06:05PM  
Oct-28-20 10:13AM  
Oct-22-20 12:34PM  
Oct-19-20 08:30AM  
Oct-13-20 08:30AM  
Sep-28-20 08:30AM  
Sep-16-20 07:49AM  
Sep-09-20 08:30AM  
Aug-26-20 01:08PM  
Aug-25-20 08:38AM  
Aug-12-20 09:26AM  
Aug-11-20 06:48AM  
Aug-07-20 08:30AM  
Aug-05-20 02:01AM  
Aug-04-20 05:15PM  
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Green Kevin DennisChief Financial OfficerMay 10Sale4.9857,335285,373222,999May 12 06:36 PM
Jayaraman Vivek KChief Operating OfficerMar 14Sale5.0441,734210,320327,097Mar 15 09:59 PM
Greenman William MarinerPresident and CEOMar 14Sale5.04165,021831,6341,885,141Mar 15 10:00 PM
CORASH LAURENCE MChief Scientific OfficerMar 14Sale5.0430,307152,7352,101,434Mar 15 09:57 PM
Green Kevin DennisChief Financial OfficerMar 14Sale5.0432,102161,780251,847Mar 15 09:55 PM
Benjamin Richard JChief Medical OfficerMar 14Sale5.0430,307152,735157,383Mar 15 09:50 PM
Moore CarolSVP Reg. & QualityMar 14Sale5.0428,513143,695257,192Mar 16 06:29 PM
Menard ChrystalChief Legal OfficerMar 14Sale5.0430,307152,734149,589Mar 16 06:25 PM
Greenman William MarinerPresident and CEOFeb 25Option Exercise3.75380,0001,425,0001,902,281Mar 01 09:18 PM
Greenman William MarinerPresident and CEOFeb 25Sale5.70308,2631,757,0431,594,018Mar 01 09:18 PM
Moore CarolSVP Reg. & QualityJan 03Option Exercise3.6619,05969,756200,335Jan 05 07:24 PM
Moore CarolSVP Reg. & QualityJan 03Sale7.0019,059133,417181,276Jan 05 07:24 PM
CORASH LAURENCE MChief Scientific OfficerDec 17Option Exercise3.755,00018,7502,027,586Dec 21 05:29 PM
CORASH LAURENCE MChief Scientific OfficerDec 13Option Exercise3.7540,000150,0002,022,586Dec 15 08:57 PM
SCHULZE GAILDirectorNov 09Option Exercise2.8625,00071,50053,116Nov 09 08:43 PM
SCHULZE GAILDirectorNov 09Sale7.5425,000188,43028,116Nov 09 08:43 PM
Moore CarolSVP Reg. & QualityNov 05Option Exercise3.75110,000412,500289,555Nov 09 08:38 PM
Moore CarolSVP Reg. & QualityNov 05Sale7.94110,000873,191181,276Nov 09 08:38 PM
Benjamin Richard JChief Medical OfficerNov 03Option Exercise4.56165,000753,133176,035Nov 05 07:41 PM
Green Kevin DennisChief Financial OfficerNov 03Option Exercise3.7595,000356,250248,740Nov 05 07:47 PM
Menard ChrystalChief Legal OfficerNov 03Sale7.7040,000308,00067,038Nov 05 07:51 PM
Green Kevin DennisChief Financial OfficerNov 03Sale7.0095,741670,187152,999Nov 05 07:47 PM
Benjamin Richard JChief Medical OfficerNov 03Sale7.68165,0001,267,75076,035Nov 05 07:41 PM
Swisher Daniel N JRDirectorAug 04Option Exercise2.8612,87736,828106,231Aug 05 05:08 PM
Swisher Daniel N JRDirectorAug 04Sale6.2512,87780,48193,354Aug 05 05:08 PM
Greenman William MarinerPresident and CEOAug 03Option Exercise2.08100,000208,0001,518,672Aug 05 05:12 PM